Literature DB >> 23772645

Very late onset hepatitis-B virus reactivation following rituximab despite lamivudine prophylaxis: the need for continued vigilance.

Edward Chew1, Karin Thursky, John F Seymour.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23772645     DOI: 10.3109/10428194.2013.813502

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


× No keyword cloud information.
  2 in total

1.  Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy.

Authors:  Shigeru Kusumoto; Luca Arcaini; Xiaonan Hong; Jie Jin; Won Seog Kim; Yok Lam Kwong; Marion G Peters; Yasuhito Tanaka; Andrew D Zelenetz; Hiroshi Kuriki; Günter Fingerle-Rowson; Tina Nielsen; Eisuke Ueda; Hanna Piper-Lepoutre; Gila Sellam; Kensei Tobinai
Journal:  Blood       Date:  2018-10-19       Impact factor: 22.113

Review 2.  Hepatitis B virus infection reactivation in patients under immunosuppressive therapies: Pathogenesis, screening, prevention and treatment.

Authors:  Anna Maria Spera
Journal:  World J Virol       Date:  2022-09-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.